Latib (Imatinib)

Imatinib selectively binds to the ATP‑binding sites of BCR‑ABL, PDGFR and c‑KIT tyrosine kinases, blocking their phosphorylation activity. This inhibition stops downstream signaling pathways that promote malignant cell proliferation and survival, leading to apoptosis of the cancer cells while sparing most normal tissues. The effect is reversible and concentration‑dependent.

The dosage of Latib is individualized by the treating physician based on the specific indication, disease stage, patient weight, and organ function. The prescriber determines the appropriate strength and schedule, which may be adjusted over time according to clinical response and tolerability. Patients should follow the exact dosing instructions provided by their healthcare professional.

Imatinib is classified as pregnancy category D, indicating evidence of risk to the fetus; it should be used only when the potential benefits justify the risk. Breastfeeding is not recommended because the drug can be excreted in milk and may harm the infant. Women of childbearing potential should discuss contraception and pregnancy planning with their clinician.

To request Latib, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details—including any temperature control if required—and assists with import documentation.

The primary alternative to imatinib is the newer generation BCR‑ABL inhibitors such as dasatinib or nilotinib, which may offer activity against certain resistant mutations but can have different safety profiles. Imatinib remains the first‑line standard for many patients due to its extensive clinical experience, well‑characterized efficacy, and generally manageable toxicity compared with some newer agents.

Latib tablets should be stored at temperatures below 25 °C (77 °F). Keep them in the original container, protect from moisture and direct light, and ensure the packaging remains tightly closed. Do not store in bathrooms or near heat sources. Proper storage maintains drug stability and potency throughout its shelf life.

Latib is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless specifically instructed by a healthcare professional. Dosing times (e.g., with or without food) are determined by the prescriber based on the individual treatment plan and tolerability.

Serious adverse events linked to imatinib include hepatotoxicity, severe neutropenia, cardiac failure, pulmonary hypertension, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for liver function, blood counts, cardiac status, and any signs of severe skin or respiratory problems, and report symptoms promptly.

Latib is contraindicated in patients with known hypersensitivity to imatinib or any of its excipients. It should also be avoided in individuals with severe hepatic impairment or uncontrolled cardiac disease unless the benefits outweigh the risks. Pregnant women, nursing mothers, and patients taking strong CYP3A4 inhibitors without dose adjustment should discuss alternatives with their physician.